Last reviewed · How we verify

NCT06717048

Minimum Power and Frequency of Repeated Low-level Red-light to Effectively Control Myopia Progression

Recruiting now NA Last updated 4 December 2024
What this trial tests

NA trial testing Repeated Low-level Red-light in Myopia in 108 participants. Currently enrolling.

Timeline
9 December 2024
Primary endpoint
9 April 2025
9 June 2025

Quick facts

Lead sponsorShanghai Eye Disease Prevention and Treatment Center
PhaseNA
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationnon randomized
Designsequential
Maskingquadruple
Primary purposetreatment
Enrollment108
Start date9 December 2024
Primary completion9 April 2025
Estimated completion9 June 2025
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

Shanghai Eye Disease Prevention and Treatment Center — full company profile →

Who can join

Adults 8 to 10, any sex, with Myopia or Refractive Error - Myopia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To explore the minimum power and frequency of Repeated Low-level Red-light (RLRL) to control myopia progression in low-myopic children aged 8-10 years, and the rebound effect of low-myopic children after discontinuation of RLRL with different combinations of power and frequency.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Myopia

Currently open trials in the same condition.

Other Shanghai Eye Disease Prevention and Treatment Center trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06717048.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing